Compare Natera Inc. Common Stock (NTRA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while ProShares UltraPro S&P500 trades at $148.69 (market cap $5.68B). The key difference: Natera Inc. Common Stock is far larger — about 10× ProShares UltraPro S&P500's market cap, and ProShares UltraPro S&P500 is more actively traded (1,616,348 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| NTRA | UPRO | |
|---|---|---|
Market Cap | $57.03B | $5.68B |
Volume | 1,131,157 | 1,616,348 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $157.66 |
52-Week Low | $179.42 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
UPRO trades at $155.38, showing minimal daily movement with a slight 0.05% decline. The technical outlook remains bullish with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment for this leveraged ETF.
As a leveraged S&P 500 ETF, UPRO's performance is tied to broader market movements. Current technical strength supports near-term upside potential, but elevated RSI levels and slowing earnings growth projections for the underlying index present headwinds. The ETF's leveraged structure amplifies both gains and losses, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
